Fluticasone and budesonide nanosuspensions for pulmonary delivery: Preparation, characterization, and pharmacokinetic studies

Yang, Jerry Z.; Young, Anthony L.; Chiang, Po‐Chang; Thurston, Archie; Pretzer, Denise K.

doi:10.1002/jps.21380

Cited by 71 publications

(31 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The X-ray diffraction patterns showed sharp diffraction peaks suggesting that both fluticasone as received and nanoparticles were crystalline (Fig. 8) (Louey et al, 2004; Murnane et al, 2008a; Yang et al, 2008a). The pattern of fluticasone nanoparticle agglomerates showed features of l -leucine and fluticasone nanoparticles.…”

Section: Resultsmentioning

confidence: 99%

“…Asthma and chronic obstructive pulmonary disease (COPD) are currently treated using either nebulizers, pressurized metered dose inhalers or dry powder inhalers (Dalby and Suman, 2003; Murnane et al, 2008b; Yang et al, 2008a). A major determinant of aerosol deposition in the respiratory tract is the aerodynamic size of particles and the polydispersity (Louey et al, 2004; Pilcer and Amighi, 2010; Pritchard, 2001).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols

El-Gendy

Pornputtapitak

Berkland

2011

European Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Particle engineering strategies remain at the forefront of aerosol research for localized treatment of lung diseases and represent an alternative for systemic drug therapy. With the hastily growing popularity and complexity of inhalation therapy, there is a rising demand for tailor-made inhalable drug particles capable of affording the most proficient delivery to the lungs and the most advantageous therapeutic outcomes. To address this formulation demand, nanoparticle agglomeration was used to develop aerosols of the asthma therapeutics, fluticasone or albuterol. In addition, a combination aerosol was formed by drying agglomerates of fluticasone nanoparticles in the presence of albuterol in solution. Powders of the single drug nanoparticle agglomerates or of the combined therapeutics possessed desirable aerodynamic properties for inhalation. Powders were efficiently aerosolized (~75% deposition determined by cascade impaction) with high fine particle fraction and rapid dissolution. Nanoparticle agglomeration offers a unique approach to obtain high performance aerosols from combinations of asthma therapeutics.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols

El-Gendy

Pornputtapitak

Berkland

2011

European Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

show abstract

“…This also includes that a different part of the body can been considered and investigated as delivery route. Transdermal patches (15)(16)(17)(18), oral capsules and pills (19)(20)(21), injectable gels (22), drug carrier suspensions (23)(24)(25) and novel inhalation systems (25,26) are examples of DDS available to date with satisfactory results in medical use. However, there are a number of key challenges that need to be addressed when developing new DDS before they can enter clinical development.…”

Section: Drug Delivery Systems (Dds)mentioning

confidence: 99%

Controlled Delivery Systems: From Pharmaceuticals to Cells and Genes

2011

View full text Add to dashboard Cite

During the last few decades, a fair amount of scientific investigation has focused on developing novel and efficient drug delivery systems. According to different clinical needs, specific biopharmaceutical carriers have been proposed. Micro- and nanoparticulated systems, membranes and films, gels and even microelectronic chips have been successfully applied in order to deliver biopharmaceuticals via different anatomical routes. The ultimate goal is to deliver the potential drugs to target tissues, where regeneration or therapies (chemotherapy, antibiotics, and analgesics) are needed. Thereby, the bioactive molecule should be protected against environmental degradation. Delivery should be achieved in a dose- and time-correct manner. Drug delivery systems (DDS) have been conceived to provide improvements in drug administration such as ability to enhance the stability, absorption and therapeutic concentration of the molecules in combination with a long-term and controlled release of the drug. Moreover, the adverse effects related with some drugs can be reduced, and patient compliance could be improved. Recent advances in biotechnology, pharmaceutical sciences, molecular biology, polymer chemistry and nanotechnology are now opening up exciting possibilities in the field of DDS. However, it is also recognized that there are several key obstacles to overcome in bringing such approaches into routine clinical use. This review describes the present state-of-the-art DDS, with examples of current clinical applications, and the promises and challenges for the future in this innovative field.

show abstract

“…The zeta potential measurements depend both on surface of the drug particles and composition of the stabiliser medium. A range of zeta potential values have previously been reported to give stable nanosuspensions, which include ±30 mV and ±20 mV for electrostatically and sterically stabilised systems, respectively (Jacobs and Müller, 2002;Yang, et al, 2008). In addition a minimum zeta potential value of ±20 mV has been proposed for stability of nanosuspensions where both ionic and non-ionic polymers and surfactants have been used as stabilizers (Ali, et al, 2009).…”

Section: Zeta Potentialmentioning

confidence: 99%

Fabrication and Evaluation of Smart Nanocrystals of Artemisinin for Antimalarial and Antibacterial Efficacy

Shah¹,

Ullah²,

Khan³

et al. 2016

AJTCAM

View full text Add to dashboard Cite

Background: Nanocrystals have the potential to substantially increase dissolution rate, solubility with subsequent enhanced bioavailability via the oral route of a range of poor water soluble drugs. Regardless of other issues, scale up of the batch size is the main issue associated with bottom up approach. Material and Methods: Smart nanocrystals of artemisinin (ARM) was produced relatively at large batch sizes (100, 200, 300 and 400ml) compared to our previously reported study by (Shah, et al., 2016). ARM nanosuspensions/nanocrystals were characterised using zeta sizer, SEM, TEM, DSC, PXRD and RP-HPLC. The nanosuspensions were finally subjected to in vitro antimalarial and antimicrobial activity. Results: The average particle size (PS) for 400 ml batches was 126.5 ±1.02 nm, and the polydispersity index (PI) was 0.194 ± 0.04. The saturation solubility of the ARM nanocrystals was substantially increased to (725.4± 2.0 µg/ml) compared to the raw ARM in water 177.4± 1.3 µg/ml and stabilizer solution (385.3± 2.0 µg/ml). The IC50 value of ARM nanosuspension against P. vivax was 65 and 21 folds lower than micronized 19.5 ng/mL and unprocessed drug (6.4 ng/mL) respectively. The ARM nanosuspension was found highly effective compared to unprocessed drug against all the tested microorganism except E. coli, Shigella and C. albican. Conclusion:The simple precipitation-ultrasonication approach was efficiently employed for fabrication of ARM nanosuspension to scale up the batch size. Similarly, the solubility, antimalarial potential and antimicrobial efficacy of ARM in the form of nanosuspension were significantly enhanced. Findings from this study can persuade research interest for further comprehensive studies using animals model.

show abstract

Fluticasone and budesonide nanosuspensions for pulmonary delivery: Preparation, characterization, and pharmacokinetic studies

Cited by 71 publications

References 22 publications

Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols

Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols

Controlled Delivery Systems: From Pharmaceuticals to Cells and Genes

Fabrication and Evaluation of Smart Nanocrystals of Artemisinin for Antimalarial and Antibacterial Efficacy

Contact Info

Product

Resources

About